How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Soluble Microneedle Patches Market
- By Application: Cosmetic Treatments, Drug Delivery, Vaccine Delivery, Diagnostic Testing, Transdermal Therapeutics
- By Material Type: Polyvinylpyrrolidone (PVP), Hyaluronic Acid, Carboxymethyl Cellulose (CMC), Polylactic Acid (PLA), Chitosan
- By End User: Hospitals, Dermatology Clinics, Pharmaceutical Companies, Research Laboratories, Home Healthcare
- By Microneedle Shape: Pyramid-shaped, Conical, Tapered, Bullet-shaped, Cylinder-shaped
- By Drug Type Delivered: Vaccines, Hormones, Analgesics, Insulin, Antibiotics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cosmetic Treatments leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Soluble Microneedle Patches Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →3M Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Zosano Pharma Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Vaxxas Pty Ltd
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →NanoPass Technologies Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Raphas Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Valeritas Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Micropoint Technologies Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →MTS Needle-Free Systems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AdminMed
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →TheraJect Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Cellaxys
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →PharmaJet Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bioservo Technologies AB
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Vaxess Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cosmetic Treatments54.0
- Drug Delivery14.4
- Vaccine Delivery7.7
- Diagnostic Testing15.8
- Transdermal Therapeutics8.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- 3M Company23.4
- Becton Dickinson and Company (BD)11.5
- Zosano Pharma Corporation12.5
- Vaxxas Pty Ltd8.0
- NanoPass Technologies Ltd.5.4
- Raphas Co. Ltd.11.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.4
- Europe25.4
- Asia Pacific22.2
- Latin America12.9
- Middle East and Africa9.2
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| 3M Company | 95 | 90 | 88 | 83 | 86 | 81 | 87 |
| Becton Dickinson and Company (BD) | 69 | 87 | 72 | 91 | 85 | 80 | 81 |
| Zosano Pharma Corporation | 77 | 77 | 72 | 66 | 85 | 85 | 77 |
| Vaxxas Pty Ltd | 68 | 68 | 69 | 57 | 58 | 58 | 63 |
| NanoPass Technologies Ltd. | 74 | 73 | 60 | 64 | 51 | 57 | 63 |
| Raphas Co. Ltd. | 61 | 63 | 62 | 57 | 54 | 50 | 58 |
| Valeritas Inc. | 66 | 53 | 64 | 51 | 45 | 48 | 55 |
| Micropoint Technologies Ltd. | 57 | 52 | 47 | 51 | 50 | 43 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- 3M Company
- Becton Dickinson and Company (BD)
- Zosano Pharma Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| 3M Company | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Becton Dickinson and Company (BD) | ✓ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Zosano Pharma Corporation | ◐ | ◐ | ✓ | − | ✓ | ✓ |
| Vaxxas Pty Ltd | ◐ | − | ✓ | ◐ | − | ◐ |
| NanoPass Technologies Ltd. | ◐ | ◐ | − | − | − | ◐ |
| Raphas Co. Ltd. | ◐ | − | ◐ | ◐ | − | − |
| Valeritas Inc. | ◐ | − | ◐ | − | − | − |
| Micropoint Technologies Ltd. | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender3
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Application in North America, then scale across Soluble Microneedle Patches Market — a $143M beachhead inside a $2.30B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Cosmetic Treatments
Best fit — highest urgency & budget in Application.
Drug Delivery
Strong fit — clear ROI and a fast path to value.
Vaccine Delivery
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Material Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Soluble Microneedle Patches Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Soluble Microneedle Patches Market is a durable-growth opportunity — $8.22B by 2033, compounding at 9.5%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Material Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Soluble Microneedle Patches Market — a $2.64B market by 2033. Plan: grow share from 7.1% to 11.7%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 11.7% | At risk |
| Revenue | $184M | $309M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 37.4% | 44.4% | At risk |
| Customer retention | 91.9% | 93.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Material Type capability
A defensible second engine — invest in Material Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Material Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $46M capacity & capability investment
- Greenlight bolt-on M&A in Material Type
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Sales deck · value proposition
Win the Soluble Microneedle Patches Market conversation — a $1.18B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Soluble Microneedle Patches Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Soluble Microneedle Patches Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Soluble Microneedle Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportSoluble Microneedle Drug Delivery System Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportSoluble Hemostatic Gauze Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportSoluble Collagen Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportSolo Suction Irrigator Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportSolitary Fibrous Tumor Treatment Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportSoliris Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportSolifenacin Succinate Tablets Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportSolid Tumor Non-Conventional Testing Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportSolid Tumor Detection Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportSolid-state X-ray Digital Radiography Devices Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportSolid State Radiation Detectors Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy